On 12/15/2025 TuHURA's CVR paid out shares. As a participant in the original transaction, my account had 331 HURA shared deposited into the account. The announcement of this transaction can be found at the following link. https://ir.tuhurabio.com/news-events/press-releases/detail/34/tuhura-biosciences-announces-its-release-of-kintaras-contingent-value-right-cvr-as-kintaras-rem-001-meets-primary-safety-endpoint-achieving-contractual-milestone KTRA was the original purchase as part of a merger agreement with HURA as the resulting entity. With an initial outlay of $2,239.48. Initial payout was $2,277.72. Essentially, the proceeds of these shares are all profit.

Reduced risk by purchasing wings for back ratios bringing risk to almost even. /MES 1 month risk profile shows 13.80% probability of loss on current positions. This is due to one of the previous back ratios expiring today. It was providing the downside protection previously. /ES 1 month risk profile shows 0.00% probability of loss on current positions.

The cash from the ADVM transaction has been returned to account. Current risk capital is $1,110. If the Ixo-vec is approved in the US prior to December 2032, my expected payout will be $2,670. If net worldwide sales exceed $1B by December 2035, an additional payout of $10,695. This is essentially a long term option with an over 10:1 payout in the next ten years. /MES 1 month risk profile shows 0.00% probability of loss on current positions. /ES 1 month risk profile shows 0.00% probability of loss on current positions.

Adverium (ADVM) to be acquired by Lilly. $3.56/share + 1 CVR per share entitling holders to an additional $8.91/share under the following conditions: if and when the following milestones are achieved: • Up to $1.78 per CVR in cash payable upon U.S. approval of Ixo-vec prior to the seventh anniversary of closing. • Up to $7.13 per CVR in cash payable upon the first achievement of annual worldwide net sales of Ixo-vec by Lilly, its affiliates or licensees exceeding $1.0 billion dollars prior to the tenth anniversary of closing. Recent price per share is $4.26/share. With the payout of 3.56 per share upon acquisition completion prospective participants can risk $0.80 cents per share with a possible payout of $8.91/share over the next ten years. 10:1 risk reward ratio. Announcement below: https://www.sec.gov/Archives/edgar/data/59478/000119312525250031/d234815dex991.htm 14D9 https://www.sec.gov/Archives/edgar/data/1501756/000119312525272604/d91171dsc14d9.htm